Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Brendan Kelley

Neurology Columbus, OH Medical Doctor

NPI 1578672440 CMS profile 298833

2050 Kenny Rd, Columbus, OH 43221

Open in the dashboard

General payments

$49,500

54 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$830,349 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Brendan Kelley of Columbus, OH is reported in the CMS Open Payments database as having received $49,500 across 54 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $830,349 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,963 15
2023 General $7,582 15
2022 General $18,955 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brendan Kelley
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Brendan Kelley were reported at $22,963. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Brendan Kelley Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $18,955 $442 $103–$2,388 $149
2023 $7,582 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $22,963 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Lilly USA, LLC $26,045 30 payments
  2. Eisai Inc. $8,757 11 payments
  3. Novo Nordisk Inc $8,150 6 payments
  4. Eli Lilly and Company $6,548 7 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $44,039 10 payments
  2. Travel and Lodging $3,417 14 payments
  3. Food and Beverage $1,937 28 payments
  4. Education $108 2 payments
Products named General payments · program years 2022–2025
  1. KISUNLA $14,668 7 payments
  2. Leqembi $146 2 payments
  3. AMYVID $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

656

Median for Neurology: 833

Drug cost

$24,178

Median for Neurology: $202,670

Branded share of claims

14%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Galantamine Er Galantamine Hbr Brand 44 $6,195
Memantine Hcl Generic 121 $5,677
Rivastigmine Generic 20 $3,969
Donepezil Hcl Generic 270 $3,428
Memantine Hcl Er Memantine Hcl Brand 22 $3,014
Bupropion Xl Bupropion Hcl Brand 26 $655
Trazodone Hcl Generic 31 $374
Sertraline Hcl Generic 54 $291
Duloxetine Hcl Generic 14 $211
Clonazepam Generic 11 $146

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$42,940

Medicare's payments for the services billed

Medicare patients

211

Average age 75

Services billed

600

93 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Alzheimer's or dementia 63%
Arthritis 52%
Depression 39%
Ischemic heart disease 31%
Diabetes 26%
Chronic kidney disease 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record